Skip to main content
Equibles

AARTIPHARM · Aarti Pharmalabs Limited

Use AARTIPHARM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AARTIPHARM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
999.35 INR -9.65 (-0.96%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 35.75K Avg daily vol (3M) 41.47K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close999.35 INR Open1,013.30 INR Day989.95–1,019.95 INR 52W close589.25–1,009.00 INR Avg vol 30d38K Last earningsOct 29, 2026 DataJan 2023–Nov 2026

Latest documents

2026
Oct 29
Earnings call
Q2 revenue rises 47%, CDMO growth guidance maintained

Aarti Pharmalabs reported Q2 FY27 revenue of INR613 crores, up 47% Y-o-Y, with EBITDA of INR136 crores and PAT of INR66 crores. It maintained 40% to 50% CDMO revenue growth guidance and targets full Xanthine capacity by end of FY27.

5 source passages
Moving on to our standalone financial for Q2 FY27, Aarti Pharmalabs maintained strong momentum delivering its highest ever quarterly revenue of INR613 crores as compared to INR417 crores, which is 47% increase Y-o-Y basis. The EBITDA was INR136 crores as compared to INR74 crores in the corresponding previous period of the previous year and that is an increase of 84% Y-o-Y. The profit after tax for the Q2 financial year 27 was INR66 crores as compared to INR24 crores a year back, which is which was 2.75x the increase on last year's low base. We remain on track to achieve our target of 40% to 50% revenue growth over last year on this business segment. The ramp-up of xanthine expanded capacity is progressing and we plan to achieve the full capacity by the end of FY27 and we will achieve the utilization sequentially in the next year. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲19.9% 5.38B INR 739.88M INR '25 Q3 ▲11.5% 5.64B INR 883.41M INR '25 Q4 ▼30.5% 3.86B INR 495.01M INR '26 Q1 ▼8.7% 4.18B INR 285.65M INR '26 Q2 ▼19.6% 4.32B INR 463.92M INR '26 Q3 ▲3.3% 5.83B INR 611.24M INR '26 Q4 ▲38.7% 5.36B INR 761.43M INR '27 Q1 LATEST ▲45.9% 6.10B INR 689.19M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 589.25 INR Now 999.35 INR · 98% Range high 1,009.00 INR
vs 200-day avg +32% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:AARTIPHARM +7.6% +15.8% +40.7% +14.4% +32.8%

Exchange listing

Market
XBOM
Ticker
AARTIPHARM
ISIN
INE0LRU01027
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.aartipharmalabs.com/
Investor relations
https://www.aartipharmalabs.com/investors-relations/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-09-15 2.00 INR
2026-02-16 1.50 INR
2025-09-15 2.50 INR
2025-02-14 2.50 INR
2024-07-31 1.00 INR
2024-02-16 2.00 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-10-29 Transcript
    Earnings Call
  • Earnings call · Q1 2027 2026-08-10
    Earnings Call
  • Earnings call · Q4 2026 2026-05-26 Transcript
    Earnings Call
  • Earnings call · Q3 2026 2026-02-10 Audio Transcript
    “Aarti Pharmalabs Q3 and 9M FY "26 Earnings Conference Call”